← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
coblopasvir
J05AP12
Forms & Strengths
- Tablets: 75mg
- Fixed-dose combination with sofosbuvir, 75mg/400mg
Adult Dosing
- Recommended dose: 75mg once daily in combination with sofosbuvir 400mg
- Duration of treatment varies by hepatitis C virus genotype and patient population
Pediatric Dosing
- Safety and efficacy not established in patients less than 18 years old
Indications
- Treatment of chronic hepatitis C virus (HCV) infection
- Genotypes 1, 2, 3, or 4, without cirrhosis or with compensated cirrhosis
Mechanism of Action
- Direct-acting antiviral (DAA)
- Inhibits HCV NS5B polymerase
- Interferes with viral RNA replication
Contraindications
- Hypersensitivity to coblopasvir or sofosbuvir
- Concomitant use with amiodarone in patients with underlying cardiac disease
Adverse Reactions
- Headache
- Fatigue
- Nausea
- Diarrhea
Drug Interactions
- Amiodarone: increased risk of serious symptomatic bradycardia
- Anticonvulsants: decreased concentrations of coblopasvir and sofosbuvir
- Rifampin: decreased concentrations of coblopasvir and sofosbuvir
Curated Content: Needs Vetting Before Put to Clinical Use